NASDAQ:CEMI - Chembio Diagnostics Stock Price, Price Target & More

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

Chembio Diagnostics (NASDAQ:CEMI) posted its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.09. The business had revenue of $7.72 million for the quarter, compared to analyst estimates of $6.10 million. Chembio Diagnostics had a negative return on equity of 32.21% and a negative net margin of 21.28%. View Chembio Diagnostics' Earnings History.

Some companies that are related to Chembio Diagnostics include Mersana Therapeutics (MRSN), Evelo Biosciences (EVLO), Zymeworks (ZYME), Insys Therapeutics (INSY), Achillion Pharmaceuticals (ACHN), ArQule (ARQL), Aurinia Pharmaceuticals (AUPH), Clementia Pharmaceuticals (CMTA), Obseva (OBSV), Cytokinetics (CYTK), ZEALAND PHARMA/S (ZEAL), Concert Pharmaceuticals (CNCE), GTX (GTXI), Innate Pharma (IPHYF) and Sinovac Biotech (SVA).

Media coverage about CEMI stock has trended somewhat positive recently, Accern reports. The research group rates the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Chembio Diagnostics earned a media sentiment score of 0.11 on Accern's scale. They also assigned news articles about the company an impact score of 46.00 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Chembio Diagnostics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Acuta Capital Partners LLC (14.17%), ARS Investment Partners LLC (6.07%), Cortina Asset Management LLC (3.70%), Gagnon Securities LLC (1.42%), Wells Fargo & Company MN (0.99%) and Gagnon Advisors LLC (0.92%). Company insiders that own Chembio Diagnostics stock include Javan Esfandiari, Neil A Goldman, Norman H Pessin and Sharon W Klugewicz. View Institutional Ownership Trends for Chembio Diagnostics.

CEMI stock was sold by a variety of institutional investors in the last quarter, including ARS Investment Partners LLC. View Insider Buying and Selling for Chembio Diagnostics.

CEMI stock was purchased by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, Acuta Capital Partners LLC, Gagnon Securities LLC, Gagnon Advisors LLC, Wells Fargo & Company MN and Benchmark Capital Advisors. Company insiders that have bought Chembio Diagnostics stock in the last two years include Neil A Goldman and Norman H Pessin. View Insider Buying and Selling for Chembio Diagnostics.

Shares of CEMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CEMI stock can currently be purchased for approximately $9.30.

Chembio Diagnostics has a market capitalization of $131.72 million and generates $24.01 million in revenue each year. The company earns $-6,370,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Chembio Diagnostics employs 165 workers across the globe.

Chembio Diagnostics' mailing address is 3661 HORSEBLOCK ROAD, MEDFORD NY, 11763. The company can be reached via phone at 631-924-1135 or via email at [email protected]